(1) |
See Principal Stockholders above for more information about the shares held by the below identified
entities. |
Ultragenyx Collaboration Agreement
In October 2020, we entered into a collaboration and license agreement (the Collaboration Agreement), with Ultragenyx Pharmaceutical Inc.
(Ultragenyx) pursuant to which we granted Ultragenyx an exclusive worldwide license under certain intellectual property rights controlled by us. In connection with the execution of the Collaboration Agreement, we also entered into
a stock purchase agreement with Ultragenyx, pursuant to which we issued and sold 7,825,797 shares of our common stock to Ultragenyx for an aggregate purchase price of approximately $40 million, resulting in Ultragenyx becoming a holder of more
than 5% of our outstanding common stock.
Other Arrangements
We employ Annie Ganot, one of our Co-Founders and the wife of Ilan Ganot, as Vice President, Patient Advocacy.
Mr. Ganot is our CEO and a member of our Board of Directors. Ms. Ganot receives an annual salary and bonus payments of less than $251,000 in the aggregate.
In respect of his services as a consultant to us for the year ending December 31, 2020, (i) on January 2, 2020, we granted Andrey Zarur, a former
member of our Board, an option to purchase 10,000 shares of our common stock, and (ii) we paid him $58,000.
In connection with the termination of
his employment, we entered into a consulting agreement with Jorge Quiroz, M.D., our former Chief Medical Officer, effective as of January 15, 2020, pursuant to which Dr. Quiroz assisted with the transition of his duties to our executive
management team. Dr. Quiroz was compensated at a rate of $500 per hour for his services under the consulting agreement. The term of the consulting agreement continued until July 15, 2020.
In connection with the termination of his employment, we entered into a consulting agreement with Alvaro Amorrortu, our former Chief Operating Officer,
effective as of January 15, 2020, pursuant to which Mr. Amorrortu assisted with the transition of his duties to our executive management team. Mr. Amorrortu was compensated at a rate of $500 per hour for his services under the
consulting agreement. The term of the consulting agreement continued until July 15, 2020.
In respect of his services as a consultant to us for the
year ended December 31, 2020, (i) on February 10, 2020, we granted Mr. Smith an option to purchase 60,000 shares of our common stock and (ii) on June 16, 2020, we granted Mr. Smith an option to purchase 200,000 shares
of our common stock. In respect of his services as a consultant to us for the year ending December 31, 2021, on January 4, 2021, we granted Mr. Smith an option to purchase 389,000 shares of our common stock. In respect of his
services as a consultant to us for the year ended December 31, 2021, on January 4, 2021, we granted Mr. Smith an option to purchase 389,000 shares of our common stock.
In November 2020, we entered into a consulting agreement with Danforth Advisors, LLC (Danforth), an affiliate of Stephen DiPalma, our
interim chief financial officer. Pursuant to the consulting agreement, Danforth provides us with the chief financial officer services of Mr. DiPalma, and other services, including financial planning, offering support and accounting services, in
exchange for fees payable to Danforth based on hourly rates. We have paid Danforth approximately $0.9 million to date. In accordance with the consulting agreement, in November 2020, we issued to Danforth a warrant to purchase 30,000 shares of
our common stock at an exercise price per share of $3.29. The consulting agreement may be terminated by either party without cause upon 60 days prior written notice to the other party and with cause upon 30 days prior written notice to
the other party.
37